Results of ENDURANCE (E1A11) phase III trial: KRd versus VRd for initial therapy of NDMM

ENDURANCE trial: KRd versus VRd for initial therapy of NDMMПодробнее

KRd vs VRd for initial therapy of newly diagnosed multiple myelomaПодробнее

What are the results from the ENDURANCE trial that compares KRd to VRd in newly diagnosed patients?Подробнее

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее

Elotuzumab plus KRd versus KRd for newly diagnosed multiple myeloma: Phase III trial resultsПодробнее

Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in MyelomaПодробнее

ENDURANCE: RVD vs KrD for myelomaПодробнее

Dr. Kumar: Results of the ENDURANCE Trial Support Standard of Care Treatment for MyelomaПодробнее

Phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk SMMПодробнее

KRd versus VRd in patients with newly diagnosed multiple myelomaПодробнее

A Look at the ENDURANCE TrialПодробнее

KRD vs VRD in high-risk multiple myeloma prior to autoHSCTПодробнее

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed MyelomaПодробнее

Shaji Kumar, MD, shares results of the Phase 3 study regarding 1st line multiple myeloma treatmentПодробнее

Why daratumumab + VRd + cyclophosphamide might be an option to consider for high-risk NDMM?Подробнее

Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple MyelomaПодробнее

Results from FORTE trial of KRd in NDMMПодробнее

Comparing the thromboembolic risk with KRd versus VRd in newly diagnosed myelomaПодробнее

DREAMM-9: Phase III study belantamab mafodotin plus VRd vs VRd alone in transplant-ineligible NDMMПодробнее